학술논문
B17 - Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes
Document Type
Article
Author
Source
In Annals of Oncology October 2017 28 Supplement 6:vi22-vi22
Subject
Language
ISSN
0923-7534